Celsion Corp (NASDAQ:CLSN)

CAPS Rating: 1 out of 5

A biotechnology company dedicated to furthering the development and commercialization of treatment systems for cancer and other diseases using focused heat energy in combination with other therapeutic devices or heat-activated genes.

Caps

How do you think CLSN will perform against the market?

Add Stock to CAPS Watchlist

All Players

79 Outperform
24 Underperform
 

All-Star Players

5 Outperform
15 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top CLSN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Kdhard1 (< 20)
Submitted May 04, 2012

Let me start by saying this is a speculative play. Celsion currently is in Phase III of their clinical trial for treatment for liver cancer and Phase II for breast cancer. The stock has pulled well back from its highs but has held stable at its… More

zzlangerhans (99.80)
Submitted June 04, 2016

I just updated my Celsion database and I was surprised to see the company with a positive enterprise value. They had 14M cash and 6M debt as of the end of March, and they burn around 6M per quarter. They'll run out of cash around October if they… More

CLSN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CLSN.

Recs

0
Member Avatar SmartAce (99.94) Submitted: 6/1/2017 12:18:41 PM : Underperform Start Price: $2.67 CLSN Score: +50.12

90% of parenting is just screaming at your kids to stop screaming.

Recs

0
Member Avatar DigitalDisco (83.82) Submitted: 5/30/2017 4:49:23 PM : Underperform Start Price: $2.50 CLSN Score: +47.11

reverse split

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 6/4/2016 4:42:22 PM : Underperform Start Price: $20.16 CLSN Score: +108.66

I just updated my Celsion database and I was surprised to see the company with a positive enterprise value. They had 14M cash and 6M debt as of the end of March, and they burn around 6M per quarter. They'll run out of cash around October if they don't raise. The OPTIMA phase III trial of ThermoDox for liver cancer isn't projected to complete enrollment until the end of 2017, at the earliest. Euro-DIGNITY is projected to begin enrollment in H2 2016, a year and a half behind the original schedule. The wild card is GEN-1 DNA-based immunotherapy, which Celsion acquired for peanuts with the EGEN acquisition in 2014. I'm dubious about the long-term prospects for GEN-1, but once the company is desperate to dilute they could certainly foment GEN-1 into a short-term price spike.

Celsion has a colorful history as a trader's football. Lots of us clearly remember the ThermoDox cult of late 2012 and its charismatic leader who claimed to be buying more ahead of the binary, then bragged after the crash about having sold the bulk of his position at the top. I made a nice profit on puts when the stock crashed, although given the high premium it probably wasn't worth the risk. Since then I've taken a couple of stabs at a rebound, trying to time Celsion's need to manipulate their share price, but those didn't work out so well. Over the past few years I've come to realize that trying to time rebounds in bioturrds doesn't work well. The rebound rarely comes in a predictable time frame, and by the time it arrives it isn't enough to make the trade profitable. Even worse, the trader doesn't want to take a loss and fails to close the position on the spike, then ends up riding the position back down again.

The alternative trade is to look at Celsion's pipeline and financials and conclude that the stock has a high probability of losing 90% or more of its remaining value within a couple of years and shorting it. The downside here is that it leaves the trader open to the possibility of going down 100%, 200%, or even more in the short-term if the company happens to foment a spike after the short is opened. That's the position I'm in now with Nymox. However, I'm holding fast on that position and waiting for the inevitable crash. However, being subject to the whims of management on these low grade, scammy stocks is a little unnerving.

I think I've convinced myself not to short Celsion now, but I might think about doing it a little closer to the next earnings call of there hasn't been any significant change. Once people see the cash reserves under 10M they may be a little less willing to spot the company a positive enterprise value.

Leaderboard

Find the members with the highest scoring picks in CLSN.

Score Leader

TrackBreanMurray

TrackBreanMurray (77.82) Score: +403.40

The Score Leader is the player with the highest score across all their picks in CLSN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stratisticalarb 98.98 6/9/2011 Underperform 1Y $200.34 -99.33% +88.48% +187.81 0 Comment
pascella < 20 6/26/2012 Underperform 3Y $199.71 -99.33% +84.29% +183.62 0 Comment
BlacknGold2 76.77 7/5/2012 Underperform 5Y $229.32 -99.42% +77.29% +176.71 0 Comment
MFBurritoSquat 38.56 11/28/2012 Underperform 3M $462.82 -99.71% +73.91% +173.62 0 Comment
TimeToBuy 88.02 12/18/2012 Underperform 5Y $488.88 -99.73% +68.55% +168.27 0 Comment
Imhilion < 20 1/2/2013 Underperform 5Y $525.42 -99.74% +67.26% +167.00 1 Comment
headyinvestor 84.78 1/31/2013 Underperform 5Y $102.69 -98.70% +61.53% +160.22 0 Comment
4dead 37.41 4/1/2013 Underperform 5Y $64.26 -97.91% +55.00% +152.91 0 Comment
KidJones 30.36 5/24/2013 Underperform 5Y $62.37 -97.85% +47.57% +145.42 0 Comment
cavemantrader 35.64 12/19/2013 Underperform 5Y $52.36 -97.44% +33.95% +131.39 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBreanMurray 77.82 1/17/2013 Underperform NS $494.42 -99.73% +64.33% +164.06 0 Comment
TrackDawsonJames < 20 11/28/2012 Outperform NS $463.68 -99.71% +73.66% -173.37 0 Comment
TrackRothCapital 67.96 5/25/2012 Outperform NS $124.74 -98.93% +83.21% -182.13 0 Comment
TrackBreanMurray 77.82 2/16/2012 Outperform NS $138.60 +249.09% +9.76% +239.34 1/17/2013 @ $483.85 0 Comment
TrackRodmanRen < 20 10/26/2011 Outperform NS $182.70 -99.27% +95.18% -194.45 0 Comment

Featured Broker Partners